09:58:00 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


2024-11-13 Kvartalsrapport 2024-Q3
2024-08-07 Kvartalsrapport 2024-Q2
2024-05-24 X-dag ordinarie utdelning PHO 0.00 NOK
2024-05-23 Årsstämma 2024
2024-05-15 Kvartalsrapport 2024-Q1
2024-02-21 Bokslutskommuniké 2023
2023-11-08 Kvartalsrapport 2023-Q3
2023-08-09 Kvartalsrapport 2023-Q2
2023-05-10 Kvartalsrapport 2023-Q1
2023-05-04 X-dag ordinarie utdelning PHO 0.00 NOK
2023-05-03 Årsstämma 2023
2023-02-24 Bokslutskommuniké 2022
2023-02-23 Bokslutskommuniké 2022
2022-11-02 Kvartalsrapport 2022-Q3
2022-08-10 Kvartalsrapport 2022-Q2
2022-05-11 Kvartalsrapport 2022-Q1
2022-04-29 X-dag ordinarie utdelning PHO 0.00 NOK
2022-04-28 Årsstämma 2022
2022-02-23 Bokslutskommuniké 2021
2021-11-17 Kvartalsrapport 2021-Q3
2021-08-11 Kvartalsrapport 2021-Q2
2021-07-28 Extra Bolagsstämma 2021
2021-05-21 X-dag ordinarie utdelning PHO 0.00 NOK
2021-05-20 Årsstämma 2021
2021-05-19 Kvartalsrapport 2021-Q1
2021-03-03 Bokslutskommuniké 2020
2020-11-10 Kvartalsrapport 2020-Q3
2020-08-18 Kvartalsrapport 2020-Q2
2020-06-11 X-dag ordinarie utdelning PHO 0.00 NOK
2020-06-10 Årsstämma 2020
2020-05-07 Kvartalsrapport 2020-Q1
2020-02-27 Bokslutskommuniké 2019
2019-11-07 Kvartalsrapport 2019-Q3
2019-08-07 Kvartalsrapport 2019-Q2
2019-06-19 Extra Bolagsstämma 2019
2019-05-14 Kvartalsrapport 2019-Q1
2019-05-10 X-dag ordinarie utdelning PHO 0.00 NOK
2019-05-09 Årsstämma 2019
2019-02-27 Bokslutskommuniké 2018
2018-11-08 Kvartalsrapport 2018-Q3
2018-08-08 Kvartalsrapport 2018-Q2
2018-05-23 Kvartalsrapport 2018-Q1
2018-05-11 X-dag ordinarie utdelning PHO 0.00 NOK
2018-05-09 Årsstämma 2018
2018-02-27 Bokslutskommuniké 2017
2017-11-08 Kvartalsrapport 2017-Q3
2017-08-23 Kvartalsrapport 2017-Q2
2017-05-23 Kvartalsrapport 2017-Q1
2017-04-28 X-dag ordinarie utdelning PHO 0.00 NOK
2017-04-27 Årsstämma 2017
2017-02-15 Bokslutskommuniké 2016
2016-11-15 Kvartalsrapport 2016-Q3
2016-08-23 Kvartalsrapport 2016-Q2
2016-05-10 Kvartalsrapport 2016-Q1
2016-04-29 X-dag ordinarie utdelning PHO 0.00 NOK
2016-04-28 Årsstämma 2016
2016-02-11 Bokslutskommuniké 2015
2015-10-29 Kvartalsrapport 2015-Q3
2015-08-13 Kvartalsrapport 2015-Q2
2015-05-06 Kvartalsrapport 2015-Q1
2015-05-02 X-dag ordinarie utdelning PHO 0.00 NOK
2015-04-30 Årsstämma 2015
2015-02-12 Bokslutskommuniké 2014
2014-11-06 Kvartalsrapport 2014-Q3
2014-08-26 Kvartalsrapport 2014-Q2
2014-05-28 X-dag ordinarie utdelning PHO 0.00 NOK
2014-05-27 Årsstämma 2014
2014-05-07 Kvartalsrapport 2014-Q1
2014-02-27 Bokslutskommuniké 2013
2013-10-23 Kvartalsrapport 2013-Q3
2013-08-22 Kvartalsrapport 2013-Q2
2013-05-23 X-dag ordinarie utdelning
2013-05-22 Årsstämma 2013
2013-04-25 Kvartalsrapport 2013-Q1
2013-02-28 Bokslutskommuniké 2012
2012-10-26 Kvartalsrapport 2012-Q3
2012-08-24 Kvartalsrapport 2012-Q2
2012-05-10 Årsstämma 2012
2012-04-26 Kvartalsrapport 2012-Q1
2012-02-16 Bokslutskommuniké 2011
2011-10-26 Kvartalsrapport 2011-Q3
2011-08-18 Kvartalsrapport 2011-Q2
2011-04-27 Kvartalsrapport 2011-Q1
2011-04-27 Årsstämma 2011
2011-02-17 Bokslutskommuniké 2010
2010-10-27 Kvartalsrapport 2010-Q3
2010-08-19 Kvartalsrapport 2010-Q2
2010-04-28 Kvartalsrapport 2010-Q1
2010-02-19 Bokslutskommuniké 2009
2009-11-26 X-dag bonusutdelning


ListaOB Match
Photocure är verksamma inom medicinteknik. Bolaget specialiserar sig inom lösningar för fotodynamisk teknik. Idag används lösningarna för behandling av sjukdomar som föranlett cancer i urinblåsan och HPV. Huvudmarknaderna återfinns inom dermatologi och onkologi, där produkterna används av sjukhus och forskningsinstitut på global nivå. Bolaget grundades 1993 och har huvudkontor i Oslo, Norge.
2024-06-04 08:00:12
Press Release - Oslo, Norway, June 4, 2024: Photocure ASA (OSE: PHO), the
Bladder Cancer Company, today announces that it has commenced activities to
support a new initiative enabling U.S. Hospitals and Clinics to offer blue light
cystoscopy (BLC[®]) using a mobile capital equipment model. The initiative is
aligned with a recently executed agreement between Karl Storz and ForTec
Medical, aimed at providing on-demand SaphiraT BLC equipment to hospitals in the
U.S. leveraging ForTec's utilization-driven mobile equipment business model.

The mobile tower opportunity is intended to increase access to BLC by reducing
or eliminating the need for capital budget approvals and instead, enables
hospitals to utilize operating budgets to bring the benefits of BLC with
Cysview[®] to their physicians and patients. In some hospitals and clinics in
the U.S., capital budget priorities have become a rate-limiting factor for
purchasing and adopting SaphiraT equipment to improve TURBT* procedures and the
management of patients with bladder cancer.

ForTec has initiated procedures in select territories with the 6 Saphira towers
that it currently has in the field, and an expanded rollout of the program
throughout the U.S. is anticipated to commence in the third quarter of 2024 with
12 additional Saphira towers that ForTec is preparing for deployment.

ForTec focuses on the urology treatment segment, and is equipped to provide real
-time capital equipment from its warehouses across the U.S. With ForTec's
facility network located within 3 hours of >90% of all U.S. operating rooms, and
its sales force covering the 48 contiguous states in the U.S., the mobile BLC
tower opportunity has potential to significantly increase access and utilization
of BLC with Cysview for TURBT procedures. In preparation for the national
rollout, ForTec, Photocure, and Karl Storz will hold joint training and planning
sessions among their commercial organizations.

Under the mobile tower business model, hospitals or physicians can contact
ForTec to schedule cases. Once scheduled, ForTec will deliver the equipment the
day before the procedure for proper set up and care. A ForTec technician is
present during all surgical procedures. Once the procedures are completed for
the day or rental period, ForTec will return the mobile tower to its local depot
for servicing and quality control in advance of the next deployment. At any
given point in the delivery of care, Photocure, Karl Storz and ForTec will
collaborate to ensure seamless service. The per case business model has
additional benefits such as roughly doubling the number of field-based account
managers between Photocure and ForTec, marketing the use of BLC with Cysview to
ForTec's vast customer network, and ensuring that trained technicians,
functioning equipment and parts are always available on-site.

"We are very pleased that the SaphiraT mobile tower program is planned for
expansion and is expected nationally throughout the remainder of the year. In
our discussions with customers, we saw that Urologists understood the clinical
value of BLC with Cysview but in many cases, were limited by a lengthy capital
equipment approval process. Additionally, this opportunity allows Photocure
access to major hospital systems as ForTec has successfully contracted with
national GPOs and opens the opportunity to expand the installed base of BLC
throughout the United States. Photocure continues to work towards ensuring
better access to quality bladder cancer care and this partnership demonstrates
that we are implementing proactive strategies to improve that access," says
Geoff Coy, Vice President & General Manager North America at Photocure.

"Collectively all three organizations will be highly focused on driving
utilization of BLC with Cysview through this mobile solution. Hospitals will be
able to provide BLC with Cysview on a per-case-basis which allows the expense to
fall within an operational budget instead of a capital budget. Once the
hospital's capital budget frees up, hospitals may choose to acquire the SaphiraT
tower permanently."  Geoff Coy concludes.

"For over 35 years, ForTec has been successfully providing mobile technologies
to customers nationwide for urology and 10 other therapeutic areas. Hospitals
and healthcare care professionals are able to take advantage of ForTec's pay-per
-use model to gain real-time access to groundbreaking technologies and premier
service, without having to conduct an extensive capital budgeting evaluation,"
said Patrick Filipovitz, CEO of ForTec. "With our mobile SaphiraT tower
solution, we aim to expand the use of blue light cystoscopy by reducing the
barriers for healthcare institutions to gain access to this cutting-edge
equipment. In coordination with Karl Storz and Photocure, our highly trained
sales professionals and technicians will support cases and ensure safe and
proper operation of the equipment."

*TURBT: Transurethral resection of bladder tumor

Note to editors:

BLC, Hexvix and Cysview, trademarks mentioned in this release, are protected by
law and are registered trademarks of Photocure ASA.
This press release may contain product details and information which are not
valid, or a product is not accessible, in your country. Please be aware that
Photocure does not take any responsibility for accessing such information which
may not comply with any legal process, regulation, registration or usage in the
country of your origin.

About Bladder Cancer

Bladder cancer ranks as the 8[th] most common cancer worldwide - the 5[th] most
common in men - with 1 949 000 prevalent cases (5-year prevalence rate)[1a], 614
000 new cases and more than 220 000 deaths in 2022.[1b]
Approx. 75% of all bladder cancer cases occur in men.[1] It has a high
recurrence rate with up to 61% in year one and up to 78% over five years.[2]
Bladder cancer has the highest lifetime treatment costs per patient of all
Bladder cancer is a costly, potentially progressive disease for which patients
have to undergo multiple cystoscopies due to the high risk of recurrence. There
is an urgent need to improve both the diagnosis and the management of bladder
cancer for the benefit of patients and healthcare systems alike.
Bladder cancer is classified into two types, non-muscle invasive bladder cancer
(NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of
invasion in the bladder wall. NMIBC remains in the inner layer of cells lining
the bladder. These cancers are the most common (75%) of all BC cases and include
the subtypes Ta, carcinoma in situ (CIS) and T1 lesions. In MIBC the cancer has
grown into deeper layers of the bladder wall. These cancers, including subtypes
T2, T3 and T4, are more likely to spread and are harder to treat.[4]

[1 ]Globocan. a) 5-year prevalence / b) incidence/mortality by population.
Available at: https://gco.iarc.fr/today, accessed [February 2024].
[2 ]Babjuk M, et al. Eur Urol. 2019